Accel Wealth Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-22
Closed -$2K 844
2021
Q2
$2K Hold
22
﹤0.01% 854
2021
Q1
$2K Hold
22
﹤0.01% 823
2020
Q4
$2K Buy
+22
New +$2.69K ﹤0.01% 782

Other funds holding LKFT

Accel Wealth Management's LKFT Position: Q3 2021 in Review

Accel Wealth Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2021, closing a stake of 22 shares — an estimated $2K sold.

Accel Wealth Management first reported a position in LKFT in Q4 2020 and held it in 3 quarters. The position peaked at $2K in Q2 2021. 81 funds tracked by Wall St. Rank hold LKFT as of Q3 2021.

  • Accel Wealth Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2021 after selling out during the quarter.
  • Accel Wealth Management sold 22 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2021, an estimated $2K.
  • Accel Wealth Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 3 quarters.
  • Accel Wealth Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $2K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2021.

Based on Accel Wealth Management's 13F filing for Q3 2021, filed 4 Nov 2021.